RSV vaccine method, single dose, stronger immunity
Summary
The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.
What changed
The USPTO published a patent application for a live attenuated RSV vaccine method. The inventors claim that removing the M2-2 protein from recombinant RSV unexpectedly produces stronger immunity than previous vaccine candidates, even though viral replication is more restricted. The application covers a single-dose formulation.
This is a patent publication notice only—there are no compliance deadlines, reporting requirements, or enforcement implications for pharmaceutical companies. Competitors developing RSV vaccines should review the claims for potential freedom-to-operate concerns or licensing opportunities. The patent application number is 18898953.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD OF VACCINATION WITH AN ATTENUATED RSV VACCINE FORMULATION
Application US20260091105A1 Kind: A1 Apr 02, 2026
Inventors
Peter L. COLLINS, Ursula J. BUCHHOLZ
Abstract
Respiratory syncytial virus (RSV) infection may lead to severe respiratory illness in young children. Thus, there is a need for a live attenuated vaccine, which would mimic the natural course of infection without causing illness; however, restricting viral replication also reduces the immune response. Reported herein is a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein that surprisingly induced a stronger immune response to RSV than previous vaccine candidates despite being more restricted in replication.
CPC Classifications
A61K 39/155 A61K 9/0043 A61P 31/14 C12N 7/00 A61K 2039/5254 A61K 2039/543 A61K 2039/545 A61K 2039/55 A61K 2039/575 C12N 2760/18534 C12N 2760/18571
Filing Date
2024-09-27
Application No.
18898953
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.